Radiation oncology

August 1997
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS92
Academic Journal
Presents an abstract of the research manuscript `Health system costs resulting from unsuccessful breast cancer treatment,' by E. Wai et al.


Related Articles

  • How much does breast cancer really cost? Korn, Peter // Self;Oct94, Vol. 16 Issue 10, p168 

    Presents a case study of the cost of treating breast cancer in the United States. Scope of health insurance coverage; Consultation fees; Radiation; Hospital fees; Lumpectomy.

  • Letrozole leads the way in the treatment of breast cancer. Pene, Stacey // PharmacoEconomics & Outcomes News;1/12/2008, Issue 544, p3 

    Breast cancer affects a significant proportion of patients worldwide, and is the fifth most common cause of cancer-related death; among women, breast cancer is the most common cause of cancer-related death, resulting in 502 000 deaths worldwide. Surgery, radiation therapy, chemotherapy and...

  • Trastuzumab too "expensive" in Swiss mBC patients?  // PharmacoEconomics & Outcomes News;7/10/2010, Issue 607, p5 

    The article discusses research on the cost-effectiveness of adding trastuzumab to capecitabine in treating patients with metastatic breast cancer, referencing a study by K. W. Matter-Walstra and colleagues published in the May 5, 2010 issue of "Annals of Oncology."

  • Breast cancer vaccine potentially cost effective.  // PharmacoEconomics & Outcomes News;11/27/2010, Issue 617, p8 

    The article offers information on a study conducted by University of Philadelphia researchers, which examined whether a breast cancer vaccine is more cost effective compared with standard treatment for breast cancer prevention.

  • International Research & Opinion.  // PharmacoEconomics & Outcomes News;4/28/2012, Issue 652, p10 

    The article discusses research on the effectiveness, safety and cost effectiveness of pegfilgrastim compared with lenograstrim in treating patients with non metastatic breast cancer receiving adjuvant myelpsuppressive chemotherapy, by L. Rossi and colleagues, presented at the 8th European Breast...

  • Searching for cost-effective options in Italy.  // PharmacoEconomics & Outcomes News;11/24/2012, Issue 667, p8 

    The article focuses on two studies made by the Drug Effectiveness Evaluation Unit (UVEF) Regional Drug Coordination Centre in Verona, Italy on the cost effectiveness of nabpaclitaxel and cabazitaxel for breast cancer and metastatic hormone-refractory prostate cancer treatment, respectively.

  • Docetaxel abreast of paclitaxel in New Zealand, or not?  // PharmacoEconomics & Outcomes News;Jun2014, Vol. 704 Issue 1, p4 

    The article discusses research being done on the cost effectiveness of weekly paclitaxel and docetaxel in women with early breast cancer in New Zealand, conducted by R. Webber-Foster et al, published in the May 24, 2014 issue of "PharmacoEconomics."

  • Standard weekly paclitaxel offered greater benefit than newer, costlier treatments.  // Hem/Onc Today;8/10/2012, Vol. 13 Issue 15, p39 

    The article discusses the findings of a phase 3 randomized clinical trial which revealed the cost effectiveness of standard weekly paclitaxel treatment for patients with locally advanced or metastatic breast cancer compared to newer and more expensive weekly first-line chemotherapy drugs.

  • Keeping abreast of Oncotype DX testing.  // PharmacoEconomics & Outcomes News;4/14/2012, Issue 651, p6 

    The article discusses research on the cost effectiveness of the use of the 21-gene Oncotype DX assay recurrence score (RS) to guide antineoplastic therapy in women with early breast cancer (EBC), referencing studies presented at a breast cancer conference in Europe.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics